|
1
|
Liu H, Wang Y, Zhang Y, Song Q, Di C, Chen
G, Tang J and Ma D: TFAR19, a novel apoptosis-related gene cloned
from human leukemia cell line TF-1, could enhance apoptosis of some
tumor cells induced by growth factor withdrawal. Biochem Biophys
Res Commun. 254:203–210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spinola M, Meyer P, Kammerer S, Falvella
FS, Boettger MB, Hoyal CR, Pignatiello C, Fischer R, Roth RB,
Pastorino U, et al: Association of the PDCD5 locus with lung cancer
risk and prognosis in smokers. J Clin Oncol. 24:1672–1678. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu D, Feng Y, Cheng Y and Wang J: Human
programmed cell death 5 protein has a helical-core and two
dissociated structural regions. Biochem Biophys Res Commun.
318:391–396. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen CH, Jiang Z, Yan JH, Yang L, Wang K,
Chen YY, Han JY, Zhang JH and Zhou CM: The involvement of
programmed cell death 5 (PDCD5) in the regulation of apoptosis in
cerebral ischemia/reperfusion injury. CNS Neurosci Ther.
19:566–576. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hedenfalk I, Duggan D, Chen Y, Radmacher
M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M,
Kallioniemi OP, et al: Gene-expression profiles in hereditary
breast cancer. N Engl J Med. 344:539–548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang YH, Zhao M, Li WM and Lu YY, Chen YY,
Kang B and Lu YY: Expression of programmed cell death 5 gene
involves in regulation of apoptosis in gastric tumor cells.
Apoptosis. 11:993–1001. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li H, Wang Q, Gao F, Zhu F, Wang X, Zhou
C, Liu C, Chen Y, Ma C, Sun W, et al: Reduced expression of PDCD5
is associated with high-grade astrocytic gliomas. Oncol Rep.
20:573–579. 2008.PubMed/NCBI
|
|
8
|
Ruan GR, Qin YZ, Chen SS, Li JL, Ma X,
Chang Y, Wang YZ, Fu JY and Liu YR: Abnormal expression of the
programmed cell death 5 gene in acute and chronic myeloid leukemia.
Leuk Res. 30:1159–1165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu DZ, Cheng Y, He H, Liu HY and Liu YF:
PDCD5 expression predicts a favorable outcome in patients with
hepatocellular carcinoma. Int J Oncol. 43:821–830. 2013.PubMed/NCBI
|
|
10
|
Wang Y, Li X, Wang L, Ding P, Zhang Y, Han
W and Ma D: An alternative form of paraptosis-like cell death,
triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell
Sci. 117:1525–1532. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu L, Hu J, Zhao Y, Hu J, Xiao J, Wang Y,
Ma D and Chen Y: PDCD5 interacts with p53 and functions as a
positive regulator in the p53 pathway. Apoptosis. 17:1235–1245.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiao J, Liu C, Li G, Peng S, Hu J, Qu L,
Lv P, Zhang Y, Ma D and Chen Y: PDCD5 negatively regulates
autoimmunity by upregulating FOXP3+ regulatory T cells
and suppressing Th17 and Th1 responses. J Autoimmun. 47:34–44.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li K, Zhou Z, Wang YO, Liu J, Zhao HB,
Yang J and Wang SQ: Pretreatment of mice with oligonucleotide prop5
protects them from influenza virus infections. Viruses. 6:573–581.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu D, Yao H, Chen Y, Feng Y, Chen Y and
Wang J: The N-terminal 26-residue fragment of human programmed cell
death 5 protein can form a stable alpha-helix having unique
electrostatic potential character. Biochem J. 392:47–54. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Colin S, Jeanny JC, Mascarelli F, Vienet
R, Al-Mahmood S, Courtois Y and Labarre J: In vivo involvement of
heparan sulfate proteoglycan in the bioavailability,
internalization, and catabolism of exogenous basic fibroblast
growth factor. Mol Pharmacol. 55:74–82. 1999.PubMed/NCBI
|
|
16
|
Chen Y, Sun R, Han W, Zhang Y, Song Q, Di
C and Ma D: Nuclear translocation of PDCD5 (TFAR19): An early
signal for apoptosis? FEBS Lett. 509:191–196. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johnson VL and Hunter DJ: The epidemiology
of osteoarthritis. Best Pract Res Clin Rheumatol. 28:5–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Loeser RF: Aging and osteoarthritis: The
role of chondrocyte senescence and aging changes in the cartilage
matrix. Osteoarthritis Cartilage. 17:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng AX, Lou SQ, Zhou HW, Wang Y and Ma
DL: Expression of PDCD5, a novel apoptosis related protein, in
human osteoarthritic cartilage. Acta Pharmacol Sin. 25:685–690.
2004.PubMed/NCBI
|
|
20
|
Yi C, Ma C, Xie Z, Zhang G, Song W, Zhou X
and Cao Y: Downregulation of programmed cell death 5 by
insulin-like growth factor 1 in osteoarthritis chondrocytes. Int
Orthop. 37:937–943. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Firestein GS: Evolving concepts of
rheumatoid arthritis. Nature. 423:356–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang N, Lu HS, Guan ZP, Sun TZ, Chen YY,
Ruan GR, Chen ZK, Jiang J and Bai CJ: Involvement of PDCD5 in the
regulation of apoptosis in fibroblast-like synoviocytes of
rheumatoid arthritis. Apoptosis. 12:1433–1441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Guan Z and Ge Z: Plasma and
synovial fluid programmed cell death 5 (PDCD5) levels are inversely
associated with TNF-_α and disease activity in patients with
rheumatoid arthritis. Biomarkers. 18:155–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang JF, Guan ZP, Zhang SL, Pei Z, Chen YY
and Pan H: Programmed cell death 5 correlates with disease activity
and interleukin-17 in serum and synovial fluid of rheumatoid
arthritis patients. Chin Med J (Engl). 126:296–299. 2013.
|
|
25
|
Xiao J, Liu W, Chen Y and Deng W:
Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse
model of multiple sclerosis. J Neuroinflammation. 12:1172015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ruan GR, Zhao HS, Chang Y, Li JL, Qin YZ,
Liu YR, Chen SS and Huang XJ: Adenovirus-mediated PDCD5 gene
transfer sensitizes K562 cells to apoptosis induced by idarubicin
in vitro and in vivo. Apoptosis. 13:641–648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi L, Song Q, Zhang Y, Lou Y and Wang Y,
Tian L, Zheng Y, Ma D, Ke X and Wang Y: Potent antitumor activities
of recombinant human PDCD5 protein in combination with chemotherapy
drugs in K562 cells. Biochem Biophys Res Commun. 396:224–230. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thompson RC Jr, Cheng EY, Clohisy DR,
Perentesis J, Manivel C and Le CT: Results of treatment for
metastatic osteosarcoma with neoadjuvant chemotherapy and surgery.
Clin Orthop Relat Res. 397:240–247. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han XR, Sun Y and Bai XZ: The anti-tumor
role and mechanism of integrated and truncated PDCD5 proteins in
osteosarcoma cells. Cell Signal. 24:1713–1721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao H, Peng C, Ruan G, Zhou J, Li Y and
Hai Y: Adenovirus-delivered PDCD5 counteracts adriamycin resistance
of osteosarcoma cells through enhancing apoptosis and inhibiting
Pgp. Int J Clin Exp Med. 7:5429–5436. 2014.
|
|
31
|
Rozeman LB, Cleton-Jansen AM and
Hogendoorn PC: Pathology of primary malignant bone and cartilage
tumours. Int Orthop. 30:437–444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen C, Zhou H, Xu L, Liu X, Liu Z, Ma D,
Chen Y and Ma Q: Prognostic significance of downregulated
expression of programmed cell death 5 in chondrosarcoma. J Surg
Oncol. 102:838–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen C, Zhou H, Xu L, Xu D, Wang Y, Zhang
Y, Liu X, Liu Z, Ma D, Ma Q, et al: Recombinant human PDCD5
sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and
in vivo. Apoptosis. 15:805–813. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nanba K, Toyooka S, Soh J, Tsukuda K,
Yamamoto H, Sakai A, Ouchida M, Kobayashi N, Matsuo K, Koide N, et
al: The allelic distribution of a single nucleotide polymorphism in
the PDCD5 gene locus of Japanese non-small cell lung cancer
patients. Mol Med Rep. 1:667–671. 2008.PubMed/NCBI
|
|
35
|
Xu F, Wu K, Zhao M, Qin Y and Xia M:
Expression and clinical significance of the programmed cell death 5
gene and protein in laryngeal squamous cell carcinoma. J Int Med
Res. 41:1838–1847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Wang C, Su B, Song Q, Zhang Y, Luo
Y, Li Q, Tan W, Ma D and Wang L: Recombinant human PDCD5 protein
enhances chemosensitivity of breast cancer in vitro and in vivo.
Biochem Cell Biol. 91:526–531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fan GL, Yao Y, Yao L and Li Y: PDCD5
transfection increases cisplatin sensitivity and decreases invasion
in hepatic cancer cells. Oncol Lett. 9:411–417. 2015.
|
|
38
|
Xu HY, Chen ZW, Pan YM, Fan L, Guan J and
Lu YY: Transfection of PDCD5 effect on the biological behavior of
tumor cells and sensitized gastric cancer cells to
cisplatin-induced apoptosis. Dig Dis Sci. 57:1847–1856. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yin A, Jiang Y, Zhang X, Zhao J and Luo H:
Transfection of PDCD5 sensitizes colorectal cancer cells to
cisplatin-induced apoptosis in vitro and in vivo. Eur J Pharmacol.
649:120–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang D, Wang W, Song CL and Xia P: The
roles of serum PDCD5 in circulating CD133 positive cells of the
patients with gastric cancer. Tumour Biol. Mar 31–2016.Epub ahead
of print.
|
|
41
|
Olischar M, Stavroudis T, Karp JK,
Kaufmann WE and Theda C: Medical and ethical challenges in the case
of a prenatally undiagnosed massive congenital brain tumor. J
Perinatol. 35:773–775. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li H, Zhang X, Song X, Zhu F, Wang Q, Guo
C, Liu C, Shi Y, Ma C, Wang X, et al: PDCD5 promotes
cisplatin-induced apoptosis of glioma cells via activating
mitochondrial apoptotic pathway. Cancer Biol Ther. 13:822–830.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gao L, Ye X, Ma RQ, Cheng HY, Han HJ, Cui
H, Wei LH and Chang XH: Low programmed cell death 5 expression is a
prognostic factor in ovarian cancer. Chin Med J (Engl).
128:1084–1090. 2015. View Article : Google Scholar
|
|
44
|
Du YJ, Xiong L, Lou Y, Tan WL and Zheng
SB: Reduced expression of programmed cell death 5 protein in tissue
of human prostate cancer. Chin Med Sci J. 24:241–245. 2009.
View Article : Google Scholar
|
|
45
|
Gao M, Gao W, Wang Z, Liu Y, Li Y, Wei C,
Sun Y, Guo C, Zhang L, Wei Z, et al: The reduced PDCD5 protein is
correlated with the degree of tumor differentiation in endometrioid
endometrial carcinoma. Springerplus. 5:9882016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen LN, Wang Y, Ma DL and Chen YY: Short
interfering RNA against the PDCD5 attenuates cell apoptosis and
caspase-3 activity induced by Bax overexpression. Apoptosis.
11:101–111. 2006. View Article : Google Scholar
|
|
47
|
Xu L, Chen Y, Song Q, Xu D, Wang Y and Ma
D: PDCD5 interacts with Tip60 and functions as a cooperator in
acetyltransferase activity and DNA damage-induced apoptosis.
Neoplasia. 11:345–354. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhuge C, Chang Y, Li Y, Chen Y and Lei J:
PDCD5-regulated cell fate decision after
ultraviolet-irradiation-induced DNA damage. Biophys J.
101:2582–2591. 2011. View Article : Google Scholar
|
|
49
|
Essers PB, Klasson TD, Pereboom TC, Mans
DA, Nicastro M, Boldt K, Giles RH and MacInnes AW: The von
Hippel-Lindau tumor suppressor regulates programmed cell death
5-mediated degradation of Mdm2. Oncogene. 34:771–779. 2015.
View Article : Google Scholar
|
|
50
|
Choi HK, Choi Y, Park ES, Park SY, Lee SH,
Seo J, Jeong MH, Jeong JW, Jeong JH, Lee PC, et al: Programmed cell
death 5 mediates HDAC3 decay to promote genotoxic stress response.
Nat Commun. 6:73902015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Park SY, Choi HK, Choi Y, Kwak S, Choi KC
and Yoon HG: Deubiquitinase OTUD5 mediates the sequential
activation of PDCD5 and p53 in response to genotoxic stress. Cancer
Lett. 357:419–427. 2015. View Article : Google Scholar
|
|
52
|
Tracy CM, Gray AJ, Cuéllar J, Shaw TS,
Howlett AC, Taylor RM, Prince JT, Ahn NG, Valpuesta JM and
Willardson BM: Programmed cell death protein 5 interacts with the
cytosolic chaperonin containing tailless complex polypeptide 1
(CCT) to regulate β-tubulin folding. J Biol Chem. 289:4490–4502.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fu DZ, Cheng Y, He H, Liu HY and Liu YF:
Recombinant human PDCD5 exhibits an antitumor role in
hepatocellular carcinoma cells via clathrin-dependent endocytosis.
Mol Med Rep. 12:8135–8140. 2015.PubMed/NCBI
|
|
54
|
Xu S, Sui G, Yuan L and Zou Z: Expression
of programmed cell death 5 protein inhibits progression of lung
carcinoma in vitro and in vivo via the mitochondrial apoptotic
pathway. Mol Med Rep. 10:2059–2064. 2014.PubMed/NCBI
|
|
55
|
Murshed F, Farhana L, Dawson MI and
Fontana JA: NF-κB p65 recruited SHP regulates PDCD5-mediated
apoptosis in cancer cells. Apoptosis. 19:506–517. 2014. View Article : Google Scholar
|
